Arcellx, Inc.
ACLX
Rang in aandelen
#2743
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Aandeelprijs
$115.07
Laatst gesynchroniseerd: 2026-05-15
Marktkapitalisatie
$6.73B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
38.04%
Land
US
Handel Arcellx, Inc. (ACLX)
Categorie
Healthcare
Koersgeschiedenis voor Arcellx, Inc. (ACLX)
Hoogste slotkoers: $115.07 op 2026-05-01
Laagste slotkoers: $17.58 op 2022-02-01
Laagste slotkoers: $17.58 op 2022-02-01
Koersgeschiedenis van Arcellx, Inc. van 2022 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 30.35% |
| 2025 | -17.00% |
| 2024 | 52.40% |
| 2023 | 93.55% |
| 2022 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.15 | 8.04% |
CH
|
